安罗替尼联合PD-1单抗(AK105)治疗13例晚期转移性肝细胞肝癌的疗效及安全性评价

韩春; 叶斯斯; 李娟; 张鹏飞; 董苑梅; 白莉

doi:10.3969/j.issn.2095-5227.2020.09.005

安罗替尼联合PD-1单抗(AK105)治疗13例晚期转移性肝细胞肝癌的疗效及安全性评价

A preliminary study on effect and safety of anlotinib combined with anti-PD-1 antibody (AK105) in treatment of advanced hepatocellular carcinoma

摘要

摘要:
目的观察安罗替尼联合PD-1单抗(AK105)治疗晚期转移性肝细胞癌的疗效和不良反应。
方法选取2019年1 - 8月在我科使用安罗替尼联合PD-1单抗治疗的13例晚期原发性肝癌患者的临床资料，观察疗效及不良反应。随访时间截至2019年9月27日，
结果安罗替尼联合PD-1单抗(AK105)治疗晚期转移性肝癌主要不良反应为手足综合征、皮肤反应及高血压等，未出现3 ~ 4级不良反应。13例患者中，3例达到了部分缓解，6例获得了疾病稳定，客观缓解率为23.1%，疾病控制率为69.2%。
结论我们的初步研究显示安罗替尼联合PD-1单抗治疗晚期转移性肝癌不良反应可控，具有较好的疗效。

Abstract:
Objective To observe the effect and adverse reactions of anlotinib combined with anti-PD-1 antibody in treatment of advanced hepatocellular carcinoma.
Methods Clinical data about 13 patients with advanced hepatocellular carcinoma treated with anlotinib combined with anti-PD-1 antibody from January to August in 2019 in our department were selected, and the curative effect and adverse reactions were observed. The follow-up lasted to September 27th, 2019.
Results The main adverse reactions of anlotinib combined with anti-PD-1 antibody in the treatment of advanced hepatocellular carcinoma were hand-foot syndrome, skin reaction and hypertension. No grade 3-4 adverse reactions occurred. In the 13 cases, 3 cases achieved partial remission, and 6 cases achieved stable disease. The objective effective rate was 23.1%, and the disease control rate was 69.2%.
Conclusion Anlotinib combined with anti-PD-1 antibody (AK105) shows good curative effect in the treatment of advanced hepatocellular carcinoma with controllable adverse reactions.

HTML全文

参考文献(18)

施引文献

资源附件(0)